Gain and loss of abilities in type II SMA: A 12-month natural history study.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
09 2020
Historique:
received: 01 02 2020
revised: 08 07 2020
accepted: 08 07 2020
pubmed: 8 9 2020
medline: 4 9 2021
entrez: 7 9 2020
Statut: ppublish

Résumé

The advent of clinical trials in spinal muscular atrophy (SMA) has highlighted the need to define patterns of progression using functional scales. It has recently been suggested that the analysis of abilities gained or lost applied to functional scales better reflects meaningful changes. We defined as "gain" a positive change between scores from 0 to either 1 or 2 and as "loss" a negative change from either 2 or 1 to 0. The aim of this study was to describe, over 12 months, which abilities on the Hammersmith Functional Motor Scale Expanded (HFMSE) were more frequently lost or gained in patients with SMA II. The cohort included 614 12-month assessments from 243 patients (age range: 30 months - 63 years; mean 9.94, SD ±7.91). The peak of abilities gained occurred before the age of 5 years while the highest number of lost abilities was found in the group 5-13 years. A correlation between the HFMSE baseline score and the ordinal number of the items was found for both lost (p<0.001) or gained (p<0.001) activities. No correlation was found with SMN2 copy number. These findings will have implications for clinical trial design and for the interpretation of real-world data using new therapeutic approaches.

Identifiants

pubmed: 32893082
pii: S0960-8966(20)30164-4
doi: 10.1016/j.nmd.2020.07.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-771

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Giorgia Coratti (G)

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Simona Lucibello (S)

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Maria C Pera (MC)

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Tina Duong (T)

Department of Neurology, Stanford University, Stanford, California, United States.

Robert Muni Lofra (R)

The John Walton Muscular Dystrophy Research Centre, Newcastle University, Integrated Laboratory Medicine Directorate, Institute of Genetic Medicine, Newcastle Upon Tyne NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.

Matthew Civitello (M)

Nemours Children's Hospital, University of Central Florida College of Medicine, Orlando, United States.

Adele D'Amico (A)

Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

Nathalie Goemans (N)

Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium.

Basil T Darras (BT)

Departments of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Claudio Bruno (C)

Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Valeria A Sansone (VA)

Neurorehabilitation Unit, University of Milan, The NEMO Clinical Center in Milan, Italy.

John Day (J)

Department of Neurology, Stanford University, Stanford, California, United States.

Andres Nascimento Osorio (A)

Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain.

Francesco Muntoni (F)

Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom; NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom.

Jaccqueline Montes (J)

Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, USA; Departments of Rehabilitation and Regenerative Medicine and Neurology, Columbia University Irving Medical Center, New York, USA.

Maria Sframeli (M)

Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud, University of Messina, Messina, Italy.

Richard Finkel (R)

Nemours Children's Hospital, University of Central Florida College of Medicine, Orlando, United States.

Eugenio Mercuri (E)

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. Electronic address: eugeniomaria.mercuri@unicatt.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH